Baccarani M - Search Results

1

Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase.

Pattacini L, Mancini M, Mazzacurati L, Brusa G, Benvenuti M, Martinelli G, Baccarani M, Santucci MA. Pattacini L, et al. Among authors: baccarani m. Leuk Res. 2004 Feb;28(2):191-202. doi: 10.1016/s0145-2126(03)00218-2. Leuk Res. 2004. PMID: 14654084

2

p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.

Brusa G, Benvenuti M, Mazzacurati L, Mancini M, Pattacini L, Martinelli G, Barbieri E, Greenberger JS, Baccarani M, Santucci MA. Brusa G, et al. Among authors: baccarani m. Haematologica. 2003 Jun;88(6):622-30. Haematologica. 2003. PMID: 12801837

3

Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.

Mazzacurati L, Pattacini L, Brusa G, Mancini M, Benvenuti M, Barbieri E, Martinelli G, Baccarani M, Greenberger JS, Santucci MA. Mazzacurati L, et al. Among authors: baccarani m. Hematol J. 2004;5(2):168-77. doi: 10.1038/sj.thj.6200365. Hematol J. 2004. PMID: 15048068

4

Interferon-alfa for chronic myeloid leukemia.

Baccarani M, Russo D, Rosti G, Martinelli G. Baccarani M, et al. Semin Hematol. 2003 Jan;40(1):22-33. doi: 10.1053/shem.2003.50004. Semin Hematol. 2003. PMID: 12563609 Review.

5

The cytogenetic response as a surrogate marker of survival.

Rosti G, Testoni N, Martinelli G, Baccarani M. Rosti G, et al. Among authors: baccarani m. Semin Hematol. 2003 Apr;40(2 Suppl 2):56-61. doi: 10.1053/shem.2003.50042. Semin Hematol. 2003. PMID: 12783377 Review.

6

New tyrosine kinase inhibitors in chronic myeloid leukemia.

Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. Martinelli G, et al. Among authors: baccarani m. Haematologica. 2005 Apr;90(4):534-41. Haematologica. 2005. PMID: 15820950

7

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N, Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G. Soverini S, et al. Among authors: baccarani m. Haematologica. 2007 Mar;92(3):401-4. doi: 10.3324/haematol.10822. Haematologica. 2007. PMID: 17339191 Free article. Clinical Trial.

8

Imatinib mesylate for the treatment of chronic myeloid leukemia.

Soverini S, Martinelli G, Iacobucci I, Baccarani M. Soverini S, et al. Among authors: baccarani m. Expert Rev Anticancer Ther. 2008 Jun;8(6):853-64. doi: 10.1586/14737140.8.6.853. Expert Rev Anticancer Ther. 2008. PMID: 18533795 Review.

9

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, Baccarani M. Rosti G, et al. Among authors: baccarani m. Leuk Lymphoma. 2010 Apr;51(4):583-91. doi: 10.3109/10428191003637282. Leuk Lymphoma. 2010. PMID: 20302388 Review.

10

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

Soverini S, Rosti G, Iacobucci I, Baccarani M, Martinelli G. Soverini S, et al. Among authors: baccarani m. Oncologist. 2011;16(6):868-76. doi: 10.1634/theoncologist.2010-0388. Epub 2011 May 31. Oncologist. 2011. PMID: 21632458 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

777 results

Search Page

Filters